Repare Non Operating Income Net Other from 2010 to 2024

RPTX Stock  USD 3.32  0.17  5.40%   
Repare Therapeutics Non Operating Income Net Other yearly trend continues to be fairly stable with very little volatility. Non Operating Income Net Other is likely to outpace its year average in 2024. During the period from 2010 to 2024, Repare Therapeutics Non Operating Income Net Other regression line of annual values had significance of  0.0008 and arithmetic mean of (301,170). View All Fundamentals
 
Non Operating Income Net Other  
First Reported
2010-12-31
Previous Quarter
85.1 K
Current Value
89.4 K
Quarterly Volatility
238.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Repare Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Repare Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 2.8 M, Interest Income of 13.8 M or Depreciation And Amortization of 1.8 M, as well as many indicators such as Price To Sales Ratio of 5.71, Dividend Yield of 0.0 or PTB Ratio of 1.52. Repare financial statements analysis is a perfect complement when working with Repare Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Repare Therapeutics Correlation against competitors.
For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.

Latest Repare Therapeutics' Non Operating Income Net Other Growth Pattern

Below is the plot of the Non Operating Income Net Other of Repare Therapeutics over the last few years. It is Repare Therapeutics' Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Repare Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Non Operating Income Net Other10 Years Trend
Slightly volatile
   Non Operating Income Net Other   
       Timeline  

Repare Non Operating Income Net Other Regression Statistics

Arithmetic Mean(301,170)
Coefficient Of Variation(79.14)
Mean Deviation203,618
Median(440,000)
Standard Deviation238,332
Sample Variance56.8B
Range529.4K
R-Value0.77
Mean Square Error25B
R-Squared0.59
Significance0.0008
Slope41,007
Total Sum of Squares795.2B

Repare Non Operating Income Net Other History

202489.4 K
202385.1 K
202174 K

About Repare Therapeutics Financial Statements

Repare Therapeutics investors use historical fundamental indicators, such as Repare Therapeutics' Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Repare Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Operating Income Net Other85.1 K89.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.